Abstract 5208
Background
Length time bias is a form of selection bias that lead to the perception that screened patients have better outcome as more indolent tumors are diagnosed during screening. However, tumors diagnosed in the interval between mammographys or detected by symptom onset are likely more aggressive. The aim was to analyze using a genomic platform if unscreened tumors were more agresive than screened ones in a homogeneous cohort not affected by stage or subtype.
Methods
Since 2014 BC pts with T1-T2 N0-N1mic tumors and/or high ki67 are selected for genomic platform-based risk assessment in order to guide adjuvant treatment. We performed an exploratory retrospective cohort study in a single institution between 2014 and 2018 in operated stage I-IIA BC pts with ER and/or PR + who underwent an Oncotype risk assessment before deciding adjuvant therapy. Results of the Recurrence score (RS) were compared according to the type of diagnosis of breast cancer as 1) Screened: Diagnosis during screening (when diagnosed occurred during a foreseen mammography visit) and 2) Unscreened: Diagnosis occurred outside screening (in an interval between mammographys or by symptom onset).
Results
105 pts were included. Median age was 56.4 y (45.2-74.6 y). All patients were ER + (range 50-100%), HER2- and grade was I (12.4%) II (82,9%) or III (4.8%). Median tumor size was 13.7 mm (4-45). 89.5% were N0 and 10.5% N1mic. 68 pts (64.8%) were in the screened and 37 (35.3%) in the unscreened group. Foreseen adjuvant treatment was changed according to Oncotype results in 24.8% patients. Median RS was 18.2 (range 3-46). According to RS risk categories 81% were classified as low , 9.5% as intermediate and 9.5% as high risk. Median RS was 17.6 in the screened vs 19.2 in the unscreened group, these differences were not significant (p = 0.34). Differences by RS categories were also not significant (Chi square p = 0.67 for two categories low vs intermediate/high risk with a RR 0.92 (0.62-1.38) and p = 0.2 for three categories).
Conclusions
No risk differences according to RS was seen between screened vs unscreened patients. These suggest that length time bias in a cohort not affected by stage or subtype might have mínimum impact on screening outcomes.
Clinical trial identification
Legal entity responsible for the study
Hospital Clinico Universitario de Valencia. INCLIVA.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract